Drug Information

Drug General Information
Drug ID
D0V6OA
Former ID
DNCL002125
Drug Name
Lurbinectedin
Drug Type
Small molecular drug
Indication Leukemia [ICD9: 208.9; ICD10:C90-C95] Phase 3 [525161]
Company
PharmaMar
Formula
C41H44N4O10S
PubChem Compound ID
57327016
Target and Pathway
Target(s) Human DNA Target Info Inhibitor [532004]
References
Ref 525161ClinicalTrials.gov (NCT02421588) Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients. U.S. National Institutes of Health.
Ref 532004Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin Cancer Res. 2012 Oct 1;18(19):5399-411.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.